**Supplemental Tables**

**Table S1. Mean Difference (95% Confidence Interval) in Cognitive Outcomes Assessed using Bayley Scales of Infant Development (BSID-II) per Log Unit Increase in Perfluoroalkyl Substances at 1, 2 and 3 Years of Child’s Age Using Complete Case Analysis**

|  |  |  |  |
| --- | --- | --- | --- |
|  | **Year 1 (n=156)** | **Year 2(n=157)** | **Year 3(n=127)** |
|  | MDI | PDI | MDI | PDI | MDI | PDI |
| **PFOS** |  |  |  |  |  |  |
| Overall  | -1.15 (-4.15, 1.85) | 1.04 (-3.08, 5.15) | 2.45 (-1.81, 6.7) | -1.17 (-5.18, 2.83) | 1.48 (-2.55, 5.51) | 0 (-4.89, 4.89) |
| Female | -1.51 (-5.51, 2.48) | 0.2 (-5.28, 5.67) | 10.7 (4.97, 16.4) | 2.44 (-3.17, 8.06) | 5.28 (0.03, 10.54) | -0.41 (-6.93, 6.11) |
| Male | -0.71 (-5.1, 3.67) | 2.06 (-3.95, 8.07) | -5.47 (-11.1, 0.14) | -4.65 (-10.15, 0.86) | -3.07 (-8.8, 2.66) | 0.48 (-6.62, 7.59) |
| *P-*Interaction | 0.79 | 0.65 | <0.001 | 0.07 | 0.03 | 0.85 |
| **PFOA** |  |  |  |  |  |  |
| Overall  | -1.92 (-5.21, 1.37) | -1.96 (-6.48, 2.56) | 1.32 (-3.24, 5.88) | 0.97 (-3.3, 5.25) | 5.25 (0.64, 9.86) | 4.57 (-1.07, 10.22) |
| Female | -2.39 (-6.65, 1.87) | -2.76 (-8.6, 3.09) | 3.39 (-2.68, 9.47) | 1.18 (-4.54, 6.9) | 5.53 (-0.79, 11.85) | 8.22 (0.54, 15.89) |
| Male | -1.18 (-6.52, 4.15) | -0.72 (-8.05, 6.6) | -1.35 (-8.25, 5.55) | 0.71 (-5.78, 7.2) | 4.91 (-1.95, 11.78) | 0.29 (-8.04, 8.62) |
| *P-*Interaction | 0.73 | 0.67 | 0.31 | 0.91 | 0.90 | 0.12 |
| **PFNA** |  |  |  |  |  |  |
| Overall  | -0.86 (-3.35, 1.63) | -0.13 (-3.55, 3.29) | 1.22 (-2.53, 4.97) | -2.27 (-5.77, 1.23) | 1.63 (-1.76, 5.02) | -2.61 (-6.7, 1.48) |
| Female | -1.08 (-4.06, 1.9) | 0.77 (-3.32, 4.85) | 3.93 (-0.82, 8.67) | 0.77 (-3.32, 4.85) | 2.18 (-1.85, 6.21) | -4.43 (-9.25, 0.4) |
| Male | -0.5 (-4.18, 3.17) | -1.62 (-6.65, 3.41) | -1.93 (-6.99, 3.13) | -1.62 (-6.65, 3.41) | 0.68 (-4.36, 5.73) | 0.53 (-5.52, 6.57) |
| *P-*Interaction | 0.79 | 0.43 | 0.07 | 0.19 | 0.62 | 0.17 |
| **PFHxS** |  |  |  |  |  |  |
| Overall  | 0.13 (-2.54, 2.8) | -0.13 (-3.79, 3.53) | 1.93 (-1.79, 5.65) | 1.19 (-2.31, 4.68) | 2.89 (-0.44, 6.23) | 2.82 (-1.24, 6.89) |
| Female | 0.13 (-2.93, 3.18) | 0.16 (-4.03, 4.35) | 3.73 (-0.88, 8.34) | 1.65 (-2.7, 6) | 1.81 (-2.24, 5.86) | 3.28 (-1.67, 8.23) |
| Male | 0.15 (-4.86, 5.16) | -0.95 (-7.81, 5.91) | -1.18 (-7.19, 4.82) | 0.39 (-5.28, 6.06) | 5.07 (-0.6, 10.74) | 1.91 (-5.02, 8.83) |
| *P-*Interaction | 0.99 | 0.78 | 0.20 | 0.72 | 0.35 | 0.75 |
| **PC1** |  |  |  |  |  |  |
| Overall  | -0.46 (-1.54, 0.62) | -0.08 (-1.56, 1.41) | 0.86 (-0.65, 2.36) | -0.14 (-1.55, 1.28) | 1.29 (-0.14, 2.73) | 0.54 (-1.22, 2.3) |
| Female | -0.59 (-1.98, 0.81) | -0.11 (-2.02, 1.8) | 2.98 (0.96, 5.01) | 0.77 (-1.18, 2.73) | 1.90 (0.00, 3.8) | 0.58 (-1.75, 2.92) |
| Male | -0.27 (-1.94, 1.39) | -0.03 (-2.32, 2.26) | -1.44 (-3.55, 0.67) | -1.12 (-3.16, 0.91) | 0.54 (-1.57, 2.65) | 0.48 (-2.12, 3.08) |
| *P-*Interaction | 0.77 | 0.96 | 0.003 | 0.19 | 0.34 | 0.95 |
| **PC2** |  |  |  |  |  |  |
| Overall  | -0.06 (-1.88, 1.75) | 0.79 (-1.69, 3.26) | -0.33 (-3.06, 2.41) | -2.15 (-4.69, 0.39) | -1.79 (-4.23, 0.64) | -3.68 (-6.58, -0.78) |
| Female | -0.09 (-2.17, 1.98) | 0.58 (-1.75, 2.92) | 0.52 (-2.93, 3.96) | -1.16 (-4.35, 2.04) | -0.6 (-3.51, 2.3) | -5.3 (-8.75, -1.86) |
| Male | 0 (-2.88, 2.89) | 0.48 (-2.12, 3.08) | -1.35 (-5.09, 2.38) | -3.36 (-6.82, 0.1) | -3.78 (-7.4, -0.17) | -0.97 (-5.25, 3.31) |
| *P-*Interaction | 0.95 | 0.75 | 0.43 | 0.31 | 0.14 | 0.09 |

Models adjusted for maternal age, material hardship, parity, pre-pregnancy BMI, maternal IQ, maternal race, maternal education, family smoking status, child’s age at testing, child’s gestational age at birth, maternal demoralization, trimester on 9/11, child’s sex and child’s breastfeeding history

Abbreviations: mental development index (MDI); perfluorohexanesulfonic acid (PFHxS); perfluorononanoic acid (PFNA); perfluorooctane sulfonate (PFOS); perfluorooctanoic acid (PFOA); principal component (PC); psychomotor development index (PDI)

**Table S2. Mean Difference (95% Confidence Interval) in Cognitive Outcomes Assessed using The Wechsler Preschool and Primary Scale of Intelligence (WPPSI) per Log Unit Increase in Perfluoroalkyl Substances at Child’s Ages 4 and 6 Years Using Complete Case Analysis**

|  |  |  |
| --- | --- | --- |
|  | **Year 4 (n=124)** | **Year 6 (n=110)** |
|  | Performance IQ | Verbal IQ | Full IQ | Performance IQ | Verbal IQ | Full IQ |
| **PFOS** |  |  |  |  |  |  |
| Overall  | -1.03 (-6.34, 4.29) | -2.86 (-7.97, 2.26) | -2.43 (-7.14, 2.28) | 5.12 (-1.11, 11.36) | 4.91 (-1.83, 11.65) | 5.72 (-0.39, 11.82) |
| Female | 0.74 (-7.21, 8.69) | 3.75 (-3.71, 11.2) | 2.32 (-4.63, 9.27) | 9.18 (0.81, 17.56) | 7.28 (-1.84, 16.4) | 9.34 (1.13, 17.55) |
| Male | -2.32 (-9.2, 4.55) | -7.72 (-14.2, -1.26) | -5.92 (-11.9, 0.09) | 0.7 (-8.01, 9.42) | 2.33 (-7.16, 11.82) | 1.78 (-6.76, 10.32) |
| *P-*Interaction | 0.56 | 0.02 | 0.07 | 0.16 | 0.45 | 0.20 |
| **PFOA** |  |  |  |  |  |  |
| Overall  | 1.11 (-5.06, 7.27) | 2.55 (-3.4, 8.5) | 2.12 (-3.36, 7.59) | -6.06 (-12.46, 0.35) | 0.22 (-6.81, 7.25) | -3.09 (-9.47, 3.29) |
| Female | 5.49 (-2.98, 14.0) | 8.34 (0.26, 16.4) | 7.51 (0.06, 15.0) | -6.01 (-15.18, 3.16) | 1.34 (-8.72, 11.4) | -2.11 (-11.23, 7.02) |
| Male | -3.71 (-12.6, 5.16) | -3.81 (-12.3, 4.67) | -3.8 (-11.6, 4.00) | -6.1 (-14.99, 2.78) | -0.83 (-10.57, 8.91) | -4.02 (-12.86, 4.82) |
| *P-*Interaction | 0.14 | 0.04 | 0.04 | 0.99 | 0.76 | 0.77 |
| **PFNA** |  |  |  |  |  |  |
| Overall  | -1.38 (-5.66, 2.91) | -1.49 (-5.63, 2.65) | -1.68 (-5.49, 2.12) | 2.79 (-1.78, 7.36) | 3.08 (-1.84, 8.01) | 3.39 (-1.08, 7.87) |
| Female | -1.51 (-6.66, 3.64) | 0.19 (-4.75, 5.13) | -0.64 (-5.20, 3.92) | 4.11 (-1.22, 9.43) | 2.61 (-3.15, 8.37) | 3.8 (-1.44, 9.04) |
| Male | -1.16 (-7.37, 5.05) | -4.17 (-10.1, 1.79) | -3.34 (-8.84, 2.17) | 0.29 (-6.62, 7.2) | 3.98 (-3.49, 11.46) | 2.62 (-4.17, 9.41) |
| *P-*Interaction | 0.93 | 0.22 | 0.41 | 0.34 | 0.75 | 0.77 |
| **PFHxS** |  |  |  |  |  |  |
| Overall  | -2.43 (-6.66, 1.80) | 1.51 (-2.59, 5.61) | -0.37 (-4.16, 3.42) | 0.58 (-3.67, 4.82) | 0.71 (-3.87, 5.28) | 0.57 (-3.6, 4.75) |
| Female | -1.08 (-6.07, 3.90) | 2.92 (-1.92, 7.75) | 1.11 (-3.34, 5.57) | 2.78 (-2.23, 7.8) | 2.14 (-3.31, 7.59) | 2.71 (-2.22, 7.64) |
| Male | -5.55 (-13.0, 1.88) | -1.74 (-8.94, 5.46) | -3.79 (-10.4, 2.84) | -4.11 (-11.3, 3.05) | -2.35 (-10.14, 5.44) | -3.96 (-11.01, 3.08) |
| *P-*Interaction | 0.32 | 0.28 | 0.22 | 0.11 | 0.34 | 0.12 |
| **PC1** |  |  |  |  |  |  |
| Overall  | -0.6 (-2.54, 1.34) | -0.14 (-2.02, 1.74) | -0.44 (-2.16, 1.29) | 0.49 (-1.59, 2.57) | 1.15 (-1.08, 3.38) | 0.93 (-1.11, 2.97) |
| Female | 0.19 (-2.54, 2.92) | 2.14 (-0.43, 4.72) | 1.3 (-1.09, 3.69) | 1.88 (-0.84, 4.61) | 1.82 (-1.13, 4.76) | 2.12 (-0.55, 4.8) |
| Male | -1.36 (-4.03, 1.31) | -2.32 (-4.84, 0.19) | -2.09 (-4.43, 0.24) | -1.33 (-4.42, 1.76) | 0.28 (-3.07, 3.63) | -0.61 (-3.65, 2.42) |
| *P-*Interaction | 0.42 | 0.01 | 0.04 | 0.12 | 0.50 | 0.18 |
| **PC2** |  |  |  |  |  |  |
| Overall  | 0.08 (-3.03, 3.18) | -2.51 (-5.47, 0.46) | -1.52 (-4.27, 1.22) | 3.06 (-0.12, 6.24) | 1.51 (-1.97, 5) | 2.65 (-0.5, 5.79) |
| Female | -0.80 (-4.45, 2.86) | -2.42 (-5.92, 1.08) | -1.81 (-5.06, 1.43) | 2.78 (-0.98, 6.55) | 0.77 (-3.34, 4.88) | 1.99 (-1.72, 5.7) |
| Male | 1.63 (-2.98, 6.25) | -2.66 (-7.09, 1.76) | -1.01 (-5.11, 3.09) | 3.51 (-1.04, 8.06) | 2.72 (-2.25, 7.69) | 3.72 (-0.76, 8.21) |
| *P-*Interaction | 0.37 | 0.93 | 0.74 | 0.79 | 0.50 | 0.51 |

Models adjusted for maternal age, material hardship, parity, pre-pregnancy BMI, maternal IQ, maternal race, maternal education, family smoking status, child age at test, child’s gestational age at birth, maternal demoralization, trimester on 9/11, child sex and child breastfeeding history.

Abbreviations: perfluorohexanesulfonic acid (PFHxS); perfluorononanoic acid (PFNA); perfluorooctane sulfonate (PFOS); perfluorooctanoic acid (PFOA); principal component (PC)

**Table S3. Unadjusted Mean Difference (95% Confidence Interval) in Cognitive Outcomes Assessed using Bayley Scales of Infant Development (BSID-II) per Log Unit Increase in Perfluoroalkyl Substances at Child’s Age 1, 2 and 3 Years (n=302)**

|  |  |  |  |
| --- | --- | --- | --- |
|  | **Year 1** | **Year 2** | **Year 3** |
|  | MDI | PDI | MDI | PDI | MDI | PDI |
| **PFOS** |  |  |  |  |  |  |
| Overall | -0.13 (-2.6, 2.34) | -1.38 (-5.61, 2.85) | 2.27 (-1.94, 6.48) | -1.61 (-4.75, 1.53) | 1.91 (-1.4, 5.22) | -0.54 (-5.17, 4.09) |
| Female | -0.69 (-4.06, 2.68) | -1.26 (-6.79, 4.27) | 4.51 (-1.45, 10.47) | 0.10 (-4.27, 4.47) | 2.99 (-1.40, 7.38) | -1.32 (-7.49, 4.85) |
| Male | 0.59 (-2.85, 4.03) | -1.50 (-6.88, 3.88) | -0.38 (-5.42, 4.66) | -3.60 (-7.68, 0.48) | 0.67 (-4.05, 5.39) | 0.48 (-5.11, 6.07) |
| *P-*Interaction | 0.59 | 0.95 | 0.19 | 0.21 | 0.47 | 0.63 |
| **PFOA** |  |  |  |  |  |  |
| Overall | -0.14 (-2.79, 2.51) | -0.09 (-4.89, 4.71) | 2.53 (-1.43, 6.49) | 1.13 (-2.32, 4.58) | 4.74 (0.88, 8.6) | 2.61 (-2.49, 7.71) |
| Female | -0.67 (-4.41, 3.07) | -0.12 (-6.10, 5.86) | 2.84 (-2.80, 8.48) | 1.32 (-3.52, 6.16) | 3.97 (-1.30, 9.24) | 4.91 (-1.93, 11.75) |
| Male | -0.08 (-3.83, 3.67) | -0.41 (-6.47, 5.65) | 2.16 (-3.16, 7.48) | 0.38 (-4.38, 5.14) | 5.30 (0.33, 10.27) | -0.31 (-6.69, 6.07) |
| *P-*Interaction | 0.83 | 0.94 | 0.86 | 0.78 | 0.70 | 0.23 |
| **PFNA** |  |  |  |  |  |  |
| Overall | 0.14 (-1.6, 1.88) | -1.73 (-4.71, 1.25) | 0.34 (-3.13, 3.81) | -1.57 (-4.20, 1.06) | 0.93 (-1.62, 3.48) | -1.38 (-4.46, 1.7) |
| Female | -0.19 (-2.39, 2.01) | -1.52 (-5.09, 2.05) | 0.88 (-3.53, 5.29) | -0.81 (-4.14, 2.52) | 1.10 (-1.88, 4.08) | -2.17 (-6.07, 1.73) |
| Male | 0.60 (-1.74, 2.94) | -2.05 (-5.97, 1.87) | -0.44 (-4.49, 3.61) | -2.65 (-5.77, 0.47) | 0.68 (-2.96, 4.32) | -0.28 (-3.96, 3.40) |
| *P-*Interaction | 0.59 | 0.82 | 0.61 | 0.35 | 0.84 | 0.42 |
| **PFHxS** |  |  |  |  |  |  |
| Overall | 0.94 (-1.2, 3.08) | 0.23 (-3.26, 3.72) | 4.29 (1.27, 7.31) | 0.74 (-2.08, 3.56) | 4.87 (2.13, 7.61) | 2.93 (-0.89, 6.75) |
| Female | 0.35 (-2.35, 3.05) | -0.42 (-4.4, 3.56) | 4.66 (0.94, 8.38) | 0.88 (-2.43, 4.19) | 3.27 (-0.18, 6.72) | 2.33 (-2.12, 6.78) |
| Male | 1.57 (-1.52, 4.66) | 0.24 (-4.94, 5.42) | 3.76 (-0.74, 8.26) | 0.35 (-3.81, 4.51) | 6.95 (2.73, 11.17) | 3.50 (-2.26, 9.26) |
| *P-*Interaction | 0.54 | 0.82 | 0.75 | 0.83 | 0.18 | 0.73 |
| **PC1** |  |  |  |  |  |  |
| Overall | 0.10 (-0.76, 0.96) | -0.48 (-2.01, 1.05) | 1.11 (-0.42, 2.64) | -0.27 (-1.41, 0.87) | 1.44 (0.30, 2.58) | 0.31 (-1.38, 2.00) |
| Female | -0.14 (-1.28, 1) | -0.50 (-2.32, 1.32) | 1.58 (-0.50, 3.66) | 0.10 (-1.47, 1.67) | 1.34 (-0.13, 2.81) | 0.16 (-2.00, 2.32) |
| Male | 0.33 (-0.86, 1.52) | -0.52 (-2.47, 1.43) | 0.53 (-1.24, 2.3) | -0.79 (-2.26, 0.68) | 1.52 (-0.12, 3.16) | 0.39 (-1.65, 2.43) |
| *P-*Interaction | 0.56 | 0.99 | 0.40 | 0.39 | 0.87 | 0.86 |
| **PC2** |  |  |  |  |  |  |
| Overall | -0.21 (-1.48, 1.06) | -1.01 (-3.22, 1.20) | -1.44 (-3.58, 0.7) | -1.49 (-3.43, 0.45) | -1.86 (-3.86, 0.14) | -2.28 (-4.53, -0.03) |
| Female | -0.19 (-1.91, 1.53) | -0.88 (-3.66, 1.90) | -1.08 (-3.98, 1.82) | -1.03 (-3.46, 1.40) | -0.91 (-3.44, 1.62) | -3.25 (-6.25, -0.25) |
| Male | -0.08 (-1.83, 1.67) | -1.09 (-4.05, 1.87) | -1.82 (-4.63, 0.99) | -1.84 (-4.30, 0.62) | -2.82 (-5.45, -0.19) | -0.98 (-4.00, 2.04) |
| *P-*Interaction | 0.93 | 0.91 | 0.70 | 0.59 | 0.24 | 0.25 |

Abbreviations: mental development index (MDI); perfluorohexanesulfonic acid (PFHxS); perfluorononanoic acid (PFNA); perfluorooctane sulfonate (PFOS); perfluorooctanoic acid (PFOA); principal component (PC); psychomotor development index (PDI)

**Table S4. Unadjusted Mean Difference (95% Confidence Interval) in Cognitive Outcomes Assessed using The Wechsler Preschool and Primary Scale of Intelligence (WPPSI) per Log Unit Increase in Perfluoroalkyl Substances at 4 and 6 Years (n=302)**

|  |  |  |
| --- | --- | --- |
|  | **Year 4** | **Year 6** |
|  | Performance IQ | Verbal IQ | Full IQ | Performance IQ | Verbal IQ | Full IQ |
| **PFOS** |  |  |  |  |  |  |
| Overall | 0.51 (-4.00, 5.02) | -0.69 (-5.10, 3.72) | -0.43 (-4.47, 3.61) | 4.48 (-0.77, 9.73) | 1.78 (-3.61, 7.17) | 3.12 (-1.84, 8.08) |
| Female | -0.22 (-6.43, 5.99) | 1.73 (-4.29, 7.75) | 0.66 (-5.00, 6.32) | 0.38 (-3.97, 4.73) | 5.58 (1.29, 9.87) | 3.46 (-0.4, 7.32) |
| Male | 1.31 (-4.24, 6.86) | -3.66 (-9.55, 2.23) | -1.84 (-7.04, 3.36) | 1.16 (-4.26, 6.58) | 6.02 (0.88, 11.16) | 3.97 (-0.61, 8.55) |
| *P-*Interaction | 0.7 | 0.19 | 0.51 | 0.82 | 0.89 | 0.86 |
| **PFOA** |  |  |  |  |  |  |
| Overall | 1.55 (-3.35, 6.45) | 5.84 (1.25, 10.43) | 4.06 (0.16, 7.96) | -1.50 (-6.75, 3.75) | 5.92 (0.31, 11.53) | 2.52 (-2.5, 7.54) |
| Female | 4.86 (-1.59, 11.31) | 2.11 (-4.73, 8.95) | 3.66 (-2.61, 9.93) | 2.07 (-2.38, 6.52) | 4.16 (-0.58, 8.9) | 3.48 (-0.68, 7.64) |
| Male | 3.92 (-2.87, 10.71) | 1.32 (-5.72, 8.36) | 2.38 (-3.86, 8.62) | 0.60 (-5.41, 6.61) | 5.41 (-0.67, 11.49) | 3.22 (-2.5, 8.94) |
| *P-*Interaction | 0.82 | 0.86 | 0.74 | 0.66 | 0.74 | 0.94 |
| **PFNA** |  |  |  |  |  |  |
| Overall | -0.66 (-3.87, 2.55) | -2.03 (-4.91, 0.85) | -1.67 (-4.47, 1.13) | 3.15 (0.01, 6.29) | -1.21 (-4.62, 2.2) | 0.79 (-2.39, 3.97) |
| Female | 1.82 (-4.9, 8.54) | 6.69 (0.40, 12.98) | 4.64 (-1, 10.28) | 0.00 (-2.04, 2.04) | 1.31 (-0.65, 3.27) | 0.7 (-1.14, 2.54) |
| Male | 2.12 (-4.42, 8.66) | 6.13 (0.15, 12.11) | 4.57 (-0.73, 9.87) | 0.50 (-1.40, 2.4) | 0.33 (-1.67, 2.33) | 0.34 (-1.39, 2.07) |
| *P-*Interaction | 0.95 | 0.89 | 0.99 | 0.71 | 0.47 | 0.77 |
| **PFHxS** |  |  |  |  |  |  |
| Overall | 0.60 (-2.95, 4.15) | 5.62 (2.13, 9.11) | 3.54 (0.48, 6.6) | 1.30 (-2.78, 5.38) | 4.60 (0.64, 8.56) | 3.23 (-0.45, 6.91) |
| Female | -0.65 (-7.26, 5.96) | 4.58 (-3.02, 12.18) | 2.38 (-4.24, 9) | 1.45 (-0.63, 3.53) | 1.08 (-1.19, 3.35) | 1.36 (-0.7, 3.42) |
| Male | -1.43 (-8.51, 5.65) | 8.12 (1.06, 15.18) | 3.69 (-2.79, 10.17) | 0.86 (-1.49, 3.21) | 1.33 (-1.09, 3.75) | 1.07 (-1.13, 3.27) |
| *P-*Interaction | 0.86 | 0.46 | 0.76 | 0.67 | 0.87 | 0.83 |
| **PC1** |  |  |  |  |  |  |
| Overall | 0.18 (-1.31, 1.67) | 0.82 (-0.67, 2.31) | 0.49 (-0.84, 1.82) | 1.12 (-0.66, 2.90) | 1.16 (-0.66, 2.98) | 1.17 (-0.52, 2.86) |
| Female | -1.00 (-5.16, 3.16) | -1.11 (-4.87, 2.65) | -1.26 (-4.94, 2.42) | -1.11 (-4.52, 2.30) | -3.72 (-6.76, -0.68) | -2.79 (-5.67, 0.09) |
| Male | -0.18 (-4.20, 3.84) | -3.33 (-7.39, 0.73) | -2.26 (-5.83, 1.31) | -0.73 (-4.08, 2.62) | -5.10 (-8.07, -2.13) | -3.44 (-6.12, -0.76) |
| *P-*Interaction | 0.76 | 0.42 | 0.68 | 0.86 | 0.5 | 0.73 |
| **PC2** |  |  |  |  |  |  |
| Overall | -0.80 (-3.37, 1.77) | -4.19 (-6.40, -1.98) | -2.93 (-5.01, -0.85) | 2.12 (-0.13, 4.37) | -3.14 (-5.55, -0.73) | -0.76 (-2.97, 1.45) |
| Female | 3.40 (-0.40, 7.20) | -0.66 (-4.87, 3.55) | 1.32 (-2.62, 5.26) | 2.04 (-0.88, 4.96) | -2.48 (-5.62, 0.66) | -0.44 (-3.38, 2.50) |
| Male | 2.83 (-1.46, 7.12) | -1.98 (-6.47, 2.51) | 0.05 (-4.03, 4.13) | 1.93 (-1.25, 5.11) | -4.14 (-7.32, -0.96) | -1.44 (-4.4, 1.52) |
| *P-*Interaction | 0.83 | 0.63 | 0.62 | 0.96 | 0.43 | 0.62 |

Abbreviations: perfluorohexanesulfonic acid (PFHxS); perfluorononanoic acid (PFNA); perfluorooctane sulfonate (PFOS); perfluorooctanoic acid (PFOA); principal component (PC)